Your practice is worth more than you think. The problem is nobody knows how to buy it.
Billion-dollar transactions leave patterns that most founders only see once. CFO Opinion is the view from both sides of the table.
* * *
There is a cohort of business owners in the United States who have built genuinely valuable enterprises: strong revenue, loyal patient bases, high margins, real brand equity within their communities. Who are discovering, as they approach the point of wanting to exit, that the market for what they have built is structurally broken.
Plastic surgeons are the clearest example. A well-established aesthetic practice with a reputation built over twenty years, a full appointment book, and margins that most businesses would consider exceptional is, on paper, an attractive acquisition target. In practice it sits in a category that institutional capital has not yet worked out how to own cleanly, and that individual buyers cannot afford without the institutional infrastructure to support them.
The result is a gap between what these practices are worth and what the market is currently able to pay for them. Understanding why that gap exists is the first step to navigating it.
* * *
1. The financial blind spot that compounds everything else
Plastic surgeons are among the highest-earning professionals in the United States. Their practices are, in many cases, exceptionally profitable — high margins on elective procedures, low bad debt exposure from a predominantly self-pay patient base, and a revenue model that requires relatively modest capital investment compared to the returns it generates.
Most practitioners know this intuitively. Very few have interrogated it analytically.
The training that produces a world-class plastic surgeon does not include financial statement literacy, valuation methodology, or capital markets awareness. These are not gaps in intelligence or diligence, they are gaps in relevance. A surgeon optimising clinical outcomes and patient experience over a twenty-year career has had no professional need to understand EBITDA normalisation, balance sheet construction, or what a buyer’s CFO does with a set of management accounts.
Until the moment they want to exit. At which point they are sitting across the table from institutional buyers, PE-backed consolidators, and their advisors, all of whom understand the financial mechanics of the transaction in detail and are being asked to evaluate structures, negotiate terms, and make irrevocable decisions about documents they are reading for the first time.
The profitability of the practice compounds rather than resolves this problem. A surgeon running a highly profitable practice has had little operational pressure to focus on margins, cost structure, or financial reporting granularity. The business works. The cash flows. The detail beneath that how margins move across procedure types, what the true cost of patient acquisition is, how the P&L would look under a different cost allocation has never needed to be understood, because it has never needed to be optimised.
That detail is exactly what a buyer’s CFO will interrogate. The practitioner who cannot speak to it fluently is negotiating from a position of structural disadvantage before the conversation has properly begun.
CFO rule: financial literacy is not a prerequisite for building a successful practice. It is a prerequisite for selling one at full value. The gap between the two is where money is lost.
2. Why PE can’t own what it wants to own
Private equity has been circling the aesthetics and elective healthcare sector for over a decade. The economics are compelling: recurring revenue from a loyal patient base, high margins on elective procedures, a fragmented market with obvious consolidation opportunity, and a demographic tailwind from an aging population with disposable income and a growing appetite for aesthetic medicine.
The structural problem is clinical ownership law.
In most US states, medical practices cannot be owned by non-physicians. The corporate practice of medicine doctrine, which exists in some form in the majority of states, though its scope and application vary significantly by jurisdiction — prohibits lay entities from employing physicians or owning medical practices directly. The intent is to prevent commercial interests from interfering with clinical judgment. The effect, in the context of PE investment, is that the standard ownership model does not apply.
PE firms have developed workarounds. The most common is the Management Services Organisation structure — the PE firm owns the MSO, which provides administrative, operational, and management services to the clinical practice, which remains nominally owned by a physician. The MSO extracts value through management fees. The physician retains clinical ownership on paper while the economic upside flows to the institutional investor.
This structure works, after a fashion. But it introduces complexity, regulatory risk, and friction that straightforward ownership does not. The physician in the arrangement is not truly independent, the management agreement typically gives the MSO significant control over operational and financial decisions, but they carry the regulatory liability of ownership without the full economic benefit. And the structure requires ongoing legal maintenance that straightforward acquisition does not.
For a plastic surgeon considering an exit, the MSO model means the buyer is not actually buying the practice. They are buying a contractual relationship with it. That distinction matters enormously for valuation, for the terms of the exit, and for what the surgeon’s life looks like in the years after signing.
A practitioner without financial fluency evaluating an MSO structure for the first time is at a particular disadvantage. The headline economics may look attractive. The management fee arrangements, the control provisions buried in the services agreement, and the earn-out mechanics that determine what the surgeon ultimately receives are where the real terms live, and where the gap between what is being proposed and what is being agreed tends to be largest.
CFO rule: when an institutional buyer cannot own the asset directly, the structure they propose instead will optimise for their interests, not yours. Understand what you are actually selling before you agree to the terms.
3. The valuation problem — pricing an asset that walks out the door
The fundamental challenge in valuing a professional services practice is that the primary revenue-generating asset is not on the balance sheet. It is the practitioner.
A plastic surgery practice with strong annual revenue and high EBITDA margins is not a conventional business in the way a product company is. It is a business whose revenue is contingent on the continued presence, reputation, and clinical skill of one or two individuals and whose patient relationships are personal rather than institutional.
The standard valuation frameworks break down immediately. EBITDA multiples derived from comparable transactions in other sectors do not transfer cleanly because the earnings are not transferable in the same way. A buyer applying a market multiple to a practice where the majority of revenue follows the lead surgeon is not buying that multiple of sustainable earnings. They are buying earnings that exist today, discounted by the probability that they continue under new ownership.
That probability is not high by default. Patients choose their surgeon. The relationship is personal, often intimate, built over years of consultations and procedures. When the surgeon changes or when the patient senses that the practice has become something different, more corporate, less personal. Attrition follows. The revenue that supported the valuation does not transfer with the practice.
The honest valuation of a founder-dependent professional practice therefore requires modelling two things simultaneously: the current earnings, and the probability of those earnings surviving the transition. The gap between the two is the discount the buyer will apply explicitly or implicitly to every offer they make.
Practitioners who understand this dynamic can do something about it before they go to market. Those who discover it during a sale process have already lost the negotiating leverage to address it.
CFO rule: the value of a practice and the transferable value of a practice are different numbers. The gap between them is determined by how much of the revenue follows the practitioner rather than the business. Narrow that gap before you need to negotiate across it.
4. The succession problem — why the obvious answer is harder than it looks
The alternative to institutional capital is the organic succession route, sell to a younger surgeon, bring in a partner, develop an internal buyer over time. This is how professional practices have transferred for generations. It is also significantly harder than it was twenty years ago, for reasons that are financial rather than cultural.
The problem is debt. A newly qualified surgeon in the United States carries a substantial student debt burden before they can consider acquiring a practice. Before they are in a position to buy, they need to service that debt, establish their clinical reputation, and accumulate the capital required for a down payment on a transaction that, for a well-established practice, will be valued in the millions. The timeline to being in a financial position to acquire is long, often fifteen years or more post-qualification. By which point they may have built their own patient base and have less reason to acquire someone else’s.
The financing environment compounds this. Lenders will extend credit against the tangible assets of a practice (equipment, property, receivables), but are significantly more cautious about the intangible value, which in a professional practice is the majority of what is being bought. A lender financing the acquisition of a plastic surgery practice is financing a bet on patient retention post-transition. That bet is difficult to underwrite and attracts conservative loan-to-value ratios that leave a significant gap between the purchase price and the available financing.
The result is a buyer pool that is structurally thinner than the seller expects. The individual buyers who could in theory acquire the practice cannot finance the full valuation. The institutional buyers who have the capital cannot own the asset in the way they normally would. The market clears, but at a price that reflects the structural limitations of the buyer pool rather than the intrinsic value of what has been built.
CFO rule: the price you achieve in a sale is determined by the depth of the buyer pool as much as the quality of the asset. A thin buyer pool with structural financing constraints will compress your valuation regardless of how well the business performs. Understanding your buyer pool before you go to market is not optional.
* * *
The pattern beyond plastic surgery
The challenges facing aesthetic medicine practitioners are not unique to that sector. They are the most visible current expression of a pattern that appears across regulated professional services — dentistry, veterinary medicine, optometry, law, architecture — wherever three conditions converge.
First, a regulatory environment that limits who can own the practice. Second, a revenue model that is contingent on the personal reputation and relationships of the practitioner. Third, a buyer pool that is structurally constrained, either by the regulatory limitations on institutional ownership, by the financing gap facing individual buyers, or both.
In each of these sectors, the same dynamic plays out. The practitioner builds something genuinely valuable. The exit market fails to reflect that value. The gap between intrinsic worth and achievable price is explained away as sector-specific, as timing, as the wrong buyer at the wrong moment. It is rarely explained as what it actually is a structural feature of markets where the asset and the owner are inseparable, and where the institutions that would normally provide liquidity cannot participate on normal terms.
The practitioners who navigate this most successfully are the ones who start thinking about it earliest. Not when they are ready to exit, but when they are building. The decisions that determine the transferable value of a professional practice are made years before the sale process begins. How deliberately the practitioner has built institutional depth into the revenue base. Whether the patient relationships are personal or practice-based. How the clinical brand has been constructed around an individual or around a platform. These are not exit decisions. They are operating decisions with exit consequences.
The calibration
None of this is an argument against building a founder-led professional practice. The personal reputation and clinical excellence that creates patient loyalty is also what makes the practice worth building.
It is an argument for understanding, earlier than feels necessary, that the market for what you are building has structural limitations and that those limitations are navigable if you know they are coming.
The gap between what a practice is worth and what the market can currently pay for it is not fixed. It narrows as PE structures mature, as financing products develop, as the buyer pool deepens. But it will not narrow fast enough for the surgeon who discovers it at the point of wanting to exit.
Start earlier. Build the transferable value deliberately. When institutional capital comes calling with an MSO structure that looks like an acquisition, read it carefully, because what they are proposing and what you are agreeing to may not be the same thing.
* * *
CFO Opinion publishes twice a month for founders, family business owners, and scale-up leaders who have never had someone on the other side of the table in their corner. If this was useful, the next issue arrives in two weeks.
If you are building a founder-led business and thinking about transferable value, read this next: You spent two years optimising your business for sale. The buyer’s CFO spent two weeks working out what that cost you.